Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.37%
SPX
+0.49%
IXIC
+0.71%
FTSE
-0.12%
N225
-0.57%
AXJO
0.00%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap
236.91M
Dividend Yield
0.00%
P/E Ratio
-1.00
EPS
-2.88
Revenue
32.31M
Avg. Volume
2.38M

Recently from Cashu

publisher logo
Cashu

Editas Medicine: Nutrafol Launches 'The Menopause Edit' to Empower Women Through Awareness

2 days ago
publisher logo
Cashu

Editas Medicine: Balancing Opportunities and Challenges in Gene Editing Innovations

13 days ago
publisher logo
Cashu

Editas Medicine: Summary of Recent Developments and Stock Performance Insights

about 1 month ago

About

What does EDIT do?
Editas Medicine, headquartered in Cambridge, Massachusetts, specializes in genome editing technology and developed a proprietary CRISPR-based platform for transformative genomic medicines. Its lead program, reni-cel, aims to treat sickle cell disease and beta thalassemia.
Sector
💻 Health Care
IPO
CEO
Employees
246
Headquarters
Massachusetts, USA
Website
http://www.editasmedicine.com
Stocks
Health Care
edit
Editas Medicine
NASDAQ: EDIT
-0.17 (-5.67%)
2.83
USD
At close at Sep 19, 20:41 UTC
Summary
News
Signals
Benchmarks
Financials